CANCER AND LEUKEMIA GROUP B

癌症和白血病 B 组

• 批准号: 2390712
• 负责人: GERALD H CLAMON
• 金额: $ 8.14万
• 依托单位: UNIVERSITY OF IOWA
• 依托单位国家: 美国
• 财政年份: 1988
• 资助国家: 美国
• 起止时间: 1988-04-01 至 1998-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2390712
• 关键词: HMG coA reductases; Hodgkin's disease; acute lymphocytic leukemia; acute nonlymphocytic leukemia; antineoplastics; autologous transplantation; bone marrow transplantation; breast neoplasms; cachexia; cancer prevention; carmustine; cell cycle proteins; chlorambucil; chromosome translocation; cis platinum compound; clinical trials; colon neoplasms; colony stimulating factor; combination cancer therapy; combination chemotherapy; cooperative study; cyclophosphamide; cytokine receptors; cytosine arabinoside; deoxycoformycin; depression; doxorubicin; dyserythropoietic anemia; enzyme inhibitors; esophagus neoplasm; etoposide; farnesyl compound; fluorouracil; gene mutation; genetic regulation; geranyl compound; hairy cell leukemia; head /neck neoplasm; hematopoietic stem cells; human subject; human therapy evaluation; immunomodulators; interferon alpha; interleukin 2; lovastatin; lung neoplasms; lymphokine activated killer cell; lymphoma; medical outreach /case finding; monoclonal antibody; natural killer cells; neoplasm /cancer chemotherapy; neoplasm /cancer diagnosis; neoplasm /cancer epidemiology; neoplasm /cancer genetics; neoplasm /cancer immunotherapy; neoplasm /cancer radiation therapy; neoplasm /cancer surgery; oncogenes; passive immunization; placebos; proliferating cell nuclear antigen; rectum neoplasms; renal cell carcinoma; small cell lung cancer; tumor antigens; tumor necrosis factor alpha; vinblastine

The goals of the University of Iowa as members of the Cancer and Leukemia Group B over the next five years are: 1) to sustain our pattern of increasing accrual to CALGB trials; 2) to continue to develop programs in both clinical and basic science areas at the University of Iowa which will lead to innovative clinical trials for the group; and 3) to add further affiliates in rural areas in Iowa so that state-of-the-art cancer care can be brought to these communities too small to support cancer programs. Over the last four years of the grant, our accrual went from 98/year to 148/year. Our stated goal in the last grant was to accrue approximately 100+ patients per year. In the first three months of 1992 we have accrued 52 patients (a rate of 208/yr). We hope to average 175 pts/year in this grant period. Current or soon to be open CALGB trials initiated from the University of Iowa include: 1) subcutaneous IL-2 in advanced small cell lung cancer with assay at the University of Iowa of sIL-2 receptor and LAK cell generation; and 2) the use of stem cells to allow multiple cycles of intensive chemotherapy without autologous bone marrow transplant. Basic science programs with potential for future CALGB trials are: 1) the development of bispecific monoclonal antibodies to lymphoma cell antigens; 2) studies in vitro of HMG-CoA reductase inhibitors to block the farnesylation and geranylation necessary for RAS expression; and 3) the use of PCNA as an intermediate marker for the development of neoplasia in the lung. Medical oncologists from the University of Iowa are now serving Mount Pleasant, Iowa and Muscatine, Iowa. Affiliates are going in Mason City, Davenport, and Waterloo. We are exploring further outreach programs in towns too small to ever support a fulltime oncologist and affiliates in larger towns to bring CALGB programs to underserved rural areas of the state. This will allow accrual of minority populations in towns such as Muscatine and the poor in rural areas served by these programs. As the physicians carrying out the care will be University of Iowa faculty, we will be able to provide quality care and data in these areas.

爱荷华大学作为癌症和白血病成员的目标 B 组未来五年的目标是：1）维持我们的模式 增加 CALGB 试验的应计项目； 2）继续开发项目 爱荷华大学的临床和基础科学领域 将为该集团带来创新的临床试验； 3）添加 在爱荷华州农村地区建立了更多附属机构，以便提供最先进的癌症治疗 可以为这些太小而无法支持癌症的社区提供护理 程序。 在资助的最后四年里，我们的应计金额从每年 98 美元增加到 148/年。 我们在上一次赠款中规定的目标是积累大约 每年 100 多名患者。 1992 年前三个月，我们 累计 52 名患者（每年 208 名）。 我们希望平均每年 175 分 在本补助期内。 目前或即将开放的 CALGB 试验由大学发起 爱荷华州包括：1)皮下注射IL-2治疗晚期小细胞肺癌 在爱荷华大学进行 sIL-2 受体和 LAK 细胞测定 一代; 2) 使用干细胞实现多个循环 无需自体骨髓移植的强化化疗。 基本的 未来有可能进行 CALGB 试验的科学项目是：1) 淋巴瘤细胞双特异性单克隆抗体的开发 抗原； 2) HMG-CoA还原酶抑制剂阻断的体外研究 the farnesylation and geranylation necessary for RAS expression;和 3) 使用 PCNA 作为中间标记来开发 肺部肿瘤。 爱荷华大学的医学肿瘤学家现在正在为芒特 爱荷华州普莱森特和爱荷华州马斯卡廷。 附属公司正在梅森城， 达文波特和滑铁卢。 我们正在探索进一步的外展计划 城镇太小，无法支持全职肿瘤学家和附属机构 较大的城镇将 CALGB 计划带到服务欠缺的农村地区 状态。 这将使少数民族人口在城镇中增加，例如 这些计划为马斯卡廷和农村地区的穷人提供服务。 作为 进行护理的医生将是爱荷华大学的教职人员，我们 将能够在这些领域提供优质的护理和数据。